Impact of HIPEC (Hyperthermic Intraperitonel Chemotherapy) on Outcome For Gynecologic Cancer Patients in a Community / Teaching Hospital
Document Type
Conference Proceeding
Publication Date
10-2026
Publication Title
International Journal of Gynecological Cancer
Abstract
Introduction: To determine if HIPEC at interval debulking surgery for ovarian cancer affects outcomes. Methods: A chart review identified 63 patients who had HIPEC and 20 patients who did not at the time of interval debulking surgery. Kaplan Meier survival analysis was used to determine significance of progression free survival and overall survival. Student’s t test was used to determine significance of other variables. Results: The cohort had 63 patients who received HIPEC and 20 who did not have HIPEC at the time of interval debulking surgery. Those who received HIPEC were younger on average (p=0.047) compared to controls. HIPEC patients did have a lower mean CA125 at time of surgery (0.0558), but this did not reach significance. The HIPEC patients had a longer time to recurrence (12 months vs 8.71 months, p=0.157), longer progression free survival (22.29 months vs 20.75 months, p=0.1555) and longer overall survival (33.27 months vs 29.95 months, p=0.1533), but none of these outcomes were statistically significant. Conclusion/Implications: Patients receiving HIPEC had increased time to recurrence, progression free survival and overall survival, although this was not statistically significant. Patients selected for HIPEC were significantly younger. They also tended to have a lower mean CA125 at the time of surgery, which implies they had a better response to neoadjuvant chemotherapy. This identifies the question of whether it is HIPEC or if the patient selection for HIPEC that impacts these outcomes. Overall, in our community/teaching hospital, HIPEC increased progression free survival by 2 months and overall survival by 3 months.
Volume
36
Issue
10 Suppl 1
First Page
38
Last Page
38
Recommended Citation
Stephens J, Hans A, Seawright K, Thomas A, Rosen B, Al-Wahab Z, et al. [GadzinskiJ, Krause D]. Impact of HIPEC (hyperthermic intraperitoneal chemotherapy) on outcome for gynecologic cancer patients in a community / teaching hospital. Int J Gynecol Cancer. 2026 Oct;36(10 Suppl 1):38. doi:10.1016/j.ijgc.2026.105234
DOI
10.1016/j.ijgc.2026.105234
Comments
International Gynecological Cancer Society (IGCS) 2026 Annual Global Meeting, October 1-3, 2026, Montreal, Canada